Concurrent chemotherapy improves the overall survival of patients irradiated for locally recurrent bladder cancer

Dirk Rades*, Lisa Manig, Stefan Janssen, Steven E. Schild

*Corresponding author for this work
4 Citations (Scopus)

Abstract

Aim: To investigate the predictive value of several factors, including concurrent chemotherapy, for overall survival of patients irradiated for locally recurrent bladder cancer. Patients and Methods: Thirty patients irradiated for local recurrence of bladder cancer were included; 14 received concurrent chemotherapy. Ten factors were analyzed for overall survival: gender, age, period from bladder cancer diagnosis to irradiation of local recurrence, Karnofsky performance scale, tumour grading, pack-years smoked, smoking during radiotherapy, radiation dose, interruption of radiotherapy and concurrent chemotherapy. Results: On univariate analyses, significantly longer overall survival was found for those with age 76 years (p=0.024), better performance status (p<0.001) and those treated with concurrent chemotherapy (p<0.001). On Cox regression analysis, concurrent chemotherapy remained significantly associated with survival (risk ratio 3.82, p=0.013); a trend for association was found for performance status (risk ratio 2.50, p=0.076). Conclusion: Addition of concurrent chemotherapy to radiotherapy for locally recurrent bladder cancer resulted in improved overall survival. Concurrent radiochemotherapy should be considered when this is clinically reasonable for such patients.

Original languageEnglish
JournalAnticancer Research
Volume37
Issue number3
Pages (from-to)1485-1488
Number of pages4
ISSN0250-7005
DOIs
Publication statusPublished - 03.2017

Fingerprint

Dive into the research topics of 'Concurrent chemotherapy improves the overall survival of patients irradiated for locally recurrent bladder cancer'. Together they form a unique fingerprint.

Cite this